OnQuality recently announced positive news for its lead candidate OQL011, an ointment designed to treat Hand-Foot Skin Reaction (HFSR) by locally activating VEGF downstream signaling pathways. OnQuality reported positive topline data from part 1 of its Phase II NOVA-II trial (NCT04088318) showing that OQL011 met the study’s primary endpoint by meeting the company’s expectations of safety, efficacy and reduced patient-reported HFSR-related pain—down to grade 0 or 1 as per NCI CTCAE v5.0 grading of palmar-plantar erythrodysesthesia (PPE . . .
